Industry
AstraZeneca Says U.S. Tariffs Manageable Despite Q1 Revenue Miss and New China Fine
AstraZeneca (NASDAQ: AZN) has reassured investors that potential U.S. pharmaceutical import tariffs will have a limited impact on its financial outlook, even as the company missed first-quarter revenue estimates and faces new regulatory scrutiny in China. The Anglo-Swedish pharmaceutical giant reported Q1 revenue of $13.6 billion, falling short of analysts’ expectations of $13.8 billion. Despite